Emergent Biosolutions Inc (NYSE:EBS) CEO Daniel Abdun-Nabi sold 21,906 shares of Emergent Biosolutions stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $47.91, for a total value of $1,049,516.46. Following the sale, the chief executive officer now directly owns 226,040 shares of the company’s stock, valued at $10,829,576.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Daniel Abdun-Nabi also recently made the following trade(s):
- On Wednesday, December 13th, Daniel Abdun-Nabi sold 20,000 shares of Emergent Biosolutions stock. The shares were sold at an average price of $45.99, for a total value of $919,800.00.
- On Friday, November 3rd, Daniel Abdun-Nabi sold 31,508 shares of Emergent Biosolutions stock. The shares were sold at an average price of $42.77, for a total value of $1,347,597.16.
Shares of Emergent Biosolutions Inc (EBS) traded down $0.04 during midday trading on Friday, reaching $47.78. The company’s stock had a trading volume of 206,500 shares, compared to its average volume of 289,767. The company has a current ratio of 7.37, a quick ratio of 6.46 and a debt-to-equity ratio of 0.38. The company has a market cap of $1,980.00, a price-to-earnings ratio of 29.86, a PEG ratio of 0.92 and a beta of 1.29. Emergent Biosolutions Inc has a 1-year low of $27.94 and a 1-year high of $48.47.
Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.32. The business had revenue of $149.43 million during the quarter, compared to analyst estimates of $124.55 million. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. Emergent Biosolutions’s revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.56 EPS. equities research analysts anticipate that Emergent Biosolutions Inc will post 1.58 earnings per share for the current year.
A number of equities research analysts have weighed in on the company. Zacks Investment Research raised Emergent Biosolutions from a “hold” rating to a “strong-buy” rating and set a $53.00 target price for the company in a research report on Tuesday. Wells Fargo & Co reaffirmed an “outperform” rating and set a $43.00 target price (up from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $47.67.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Riverhead Capital Management LLC raised its position in shares of Emergent Biosolutions by 102.8% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 1,542 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Emergent Biosolutions by 23.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 587 shares in the last quarter. First Quadrant L P CA bought a new position in shares of Emergent Biosolutions in the 3rd quarter worth $157,000. Victory Capital Management Inc. bought a new position in shares of Emergent Biosolutions in the 3rd quarter worth $191,000. Finally, Meeder Asset Management Inc. raised its position in shares of Emergent Biosolutions by 94.7% in the 3rd quarter. Meeder Asset Management Inc. now owns 4,732 shares of the biopharmaceutical company’s stock worth $191,000 after acquiring an additional 2,302 shares in the last quarter. 88.44% of the stock is owned by institutional investors and hedge funds.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.